Injectable medication for brain blood vessel malformations
Part of Brain & nervous system, Genetic & congenital, Heart & circulation clinical trials.
This trial tests if injecting a medication called bevacizumab directly into certain hard-to-treat brain blood vessel malformations can help. It is for adults with large or complex malformations that have already bled or caused serious symptoms and cannot be removed with standard surgery or procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old.
- You have a brain blood vessel malformation that is large or complex (called Spetzler-Martin grade IV or V).
- Your malformation has bled in the past or is causing severe symptoms like hard-to-control seizures, compression on nearby brain tissue, or pressure symptoms.
- Your doctors have decided that your malformation cannot be treated with standard invasive methods like surgery or radiation.
- You have adequate bone marrow, liver, and kidney function, and are up to date with COVID-19 vaccines per French guidelines.
- You are not pregnant, not breastfeeding, and use effective birth control during the study and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called FCN-159 for people with a high-grade brain AVM that has never bled. The goal is to see if it can shrink the AVM or prevent future problems.
This study looks at how well the drug Bevacizumab works and how safe it is for people with HHT who have severe liver problems that cause their heart to pump too much blood. It aims to help doctors understand if this treatment can help manage these serious symptoms.
This trial tests a medication called bevacizumab (given as an IV infusion) to see if it can improve symptoms in people with brain arteriovenous malformations (AVMs) that cannot be treated with standard therapies. It is for those whose AVMs cause significant disability.
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
This trial uses a blood test to look for genetic mutations in brain arteriovenous malformations (bAVMs). It may help doctors understand these lesions better and guide treatment.
This trial tests if injecting bevacizumab into the artery that supplies the covering of the brain can help treat chronic subdural hematoma (a slow-growing collection of blood on the brain's surface). It may offer an alternative to surgery for some patients.
Hear when a new Brain Arteriovenous Malformations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.